Combined therapy in the treatment of primary mediastinal B-cell lymphoma: Conventional versus escalated chemotherapy

Annals of Hematology

Volumn 81, Issue 7, 2002, Pages 368-373

  Aviles A ^a   Garcia E L ^a   Fernandez R ^a   Gonzalez, J L ^a   Neri, N ^a   Diaz Maqueo J C ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Chemotherapy; Diffuse large cell lymphoma; Malignant lymphoma; Mediastinal lymphoma; Prognostic factors

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MANTLE FIELD RADIOTHERAPY; MEDIASTINUM LYMPH NODE; MEDIASTINUM TUMOR; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PREDNISONE; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036935085     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0473-4     Document Type: Article

References (24)

1. Aisenberg AC (1999) Primary large cell lymphoma of the medistinum. Sem Oncol 26:251-258
2. Avilés A, Delgado S, Nambo MJ, Alatriste S, Díaz-Maqueo JC (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30:799-804
3. Avilés A, Guzmán R, Delgado S, Nambo MJ, García EL, Díaz-Maqueo JC (1996) Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve prognosis in aggressive malignant lymphoma. Am J Hematol 52:275-280
4. Avilés A, Calva A, Díaz-Maqueo JC, Talavera A, Huerta-Guzmán J, Vásquez E (1997) Dose escalation of epirubicin in the CEOP-Bleo regimen. A controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma. Leuk Lymphoma 25:319-325
5. Avilés A, Talavera A, Díaz-Maqueo JC, Cleto S, Díaz NR, García EL (1998) High dose chemotherapy in the treatment of poor prognosis malignant lymphoma. Hematology 3:229-233
6. Avilés A, García R (1999) Late evaluation of cardiotoxicity in patients with malignant lymphoma treated with intensive chemotherapy regimen. Cancer Res Ther Control 10:119-122
7. Basaran M, Bavbek S, Sukar B, Eralp Y, Alici S, Tas F, Yuman F, Pegan O, Camlica H (2000) Treatment of aggressive non-Hodgkin's lymphoma with doses intensified epirubicin in combination with cyclophosphamide, vincristine and prednisone. Am J Clin Oncol 24:570-574
8. Blank N, Castellino RA (1982) The intrathoracic manifestations of the malignant lymphoma and leukemias. Sem Roentgenol 15:227-245
9. Bragg DG (1978) The clinical pathological and radiographic spectrum of the intrathoracic lymphomas. Invest Radiol 13:2-11
10. Cazals-Hatem D, Lepager E, Brice P (1996) Primary mediastinal large B-cell lymphoma. Am J Surg Pathol 20:877-888
11. DeLena M, Diamont P, Larussa V, Brandi A, Timorian A, Marzullo F, Ventrella V, Pellechia A (1995) CEOP-Bleo alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma. J Clin Oncol 13:953-960
12. Falini B, Venturi S, Martelli M, Santucci A, Pileri S, Mora E, Giovanni M, Mazza P, Martelli MF, Pasqualini L, Ballarino E, Guglielmo C, Amadori S, Poggi S, Sabatini F, Gherizauli F, Zinzani PL, Baroni CR, Mandelli F, Tura S (1995) Mediastinal large B-cell lymphoma. Clinical and immunohistochemical findings in 18 patients treated with different third-generation regimens. Br J Haematol 89:780-789
13. Gurney H, Dodwell D, Thatcher N, Tattersal N (1993) Escalating drug delivery in cancer chemotherapy. Ann Oncol 4:23-34
14. Jacobson JJ, Aisenberg AC, Lamarre L, Willey CG, Linggood RM, Mikelic LM, Harris NL (1988) Mediastinal large cell lymphoma. An uncommon subset of adults curable with combined therapy. Cancer 62:1893-1898
15. Kirn D, Mauch P, Shaffer K, Pinkus C, Shipp MA, Kaplan WD, Tung N, Wheeler C, Beard CJ, Canellos GP, Shulman LN (1993) Large-cell and immunoblastic lymphoma of the mediastinum. Prognostic features and treatment outcome in 57 patients. J Clin Oncol 11:1336-1343
16. Lazarino M, Orlandi E, Pauli M, Sträter J, Illersy L, Gambacorta M, Morra E, Lavabre-Bertrand T, Magrini C, Magenold C, Bernasconi C, Möller F (1997) Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma. A multicenter study in 106 patients. J Clin Oncol 15:1646-1653
17. Levitt L, Aisenberg A, Harris NL (1980) Primary non-Hodgkin's of the mediastinum. Cancer 68:509-514
18. Meyer RM, Quint IC, Skillings JR, Cripps MC, Bardwell VHC, Weinerman DH, Gospodarowitz MK, Burns DF, Sargeant M, Shepperd LE, Zee B, Hryniuk WH (1993) Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 329:1770-1776
19. Nair R, Ramakrishann G, Nair NN, Saikita TP, Parikh PM, Joshi SR, Soran CS, Mukhadan M, Dinshaw KY, Advanti SH (1998) A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer 82:2282-2288
20. Romaguera J, Rodriguez J, Carias L, Hagemeister FB, McLaughlin P, Rodriguez MA, Sarris AH, Yunes A, Preti A, Bachier C, Llerena E, Cabanillas F (1998) Use of the International Prognostic Index and the tumor score to detect poor-risk patients with primary mediastinal large-cell lymphoma. A study of 37 previously untreated patients. Leuk Lymphoma 28: 295-306
21. The non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 89:3909-3918
22. Sehn LH, Antin JR, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C (1998) Primary diffuse large B-cell lymphoma of the mediastinum. Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 91:717-723
23. Trump DL, Mann RB (1982) Diffuse large cell and undifferentiated lymphoma with prominent mediastinal involvement. A poor prognostic subset of patients with non-Hodgkin's lymphoma. Cancer 50:277-282
24. Zuckerman KS, Case DC, Gams RS, Pratsthofer EA (1993) Chemotherapy of intermediate-and high-grade non-Hodgkin's lymphomas with an intensive epirubicin containing regimen. Blood 82:3564-3573